We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th. BNTX’s trailing and forward P/E were 166.87 and 7.04 respectively according to Yahoo Finance.
Photo by National Cancer Institute on Unsplash
BioNTech SE (BNTX) has transitioned from a COVID-19 vaccine pioneer to a diversified biotech company with a growing focus on oncology, positioning itself for potential upside despite near-term uncertainties. After its initial success with the mRNA COVID vaccine in partnership with Pfizer, BioNTech has expanded its technology platform through strategic acquisitions, including the purchase of Chinese startup Biotheseus.
This acquisition quickly yielded a landmark deal with Bristol Myers for BNT327, generating $2 billion in upfront payments plus a 50% royalty share, highlighting BioNTech’s ability to capitalize on high-value pipeline opportunities. Financially, the company enters 2026 with a robust €17.2 billion cash position against a market capitalization of ~€22 billion, providing a strong buffer for ongoing R&D and strategic initiatives.
Operationally, BioNTech has remained cash flow positive in 2025, driven by BNT327 milestones and residual COVID vaccine sales, while its GAAP losses continue to narrow. AI-driven analyses of the oncology pipeline suggest a risk-adjusted net present value (rNPV) of €7–8 billion in a base case, implying a total equity value including cash of €24–25 billion, with a bull case reaching €32 billion if pipeline programs succeed.
Despite uncertainties around regulatory hurdles, competition, and manufacturing complexity, the market currently underprices the potential of BioNTech’s pipeline, creating a favorable risk/reward profile.
With experienced management, proven deal-making ability, and a diversified development pipeline, BioNTech represents a compelling opportunity for investors seeking exposure to innovation-driven growth in the biotechnology sector, where successful clinical readouts could unlock substantial upside. Even conservative estimates suggest that the stock trades below its intrinsic value, making it an attractive buy for those willing to navigate biotech execution risk.
Previously, we covered a bullish thesis on Moderna, Inc. (MRNA) by YouAlwaysHaveAChoice in February 2025, which highlighted upside from emerging infectious disease risks, institutional accumulation, technical signals, and options flow. MRNA’s stock price has appreciated by approximately 73.67% since our coverage. Memyselfandi007 shares a similar view but emphasizes BioNTech SE’s (BNTX) diversification into oncology, strategic deals like BNT327 with Bristol Myers, and a strong cash position supporting its pipeline value.
BioNTech SE is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held BNTX at the end of the fourth quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of BNTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BNTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
